Patient Characteristics | Â | Distribution, n (%) |
---|---|---|
Gender | Female | 19 (83) |
 | Male | 4 (17) |
Age (years) | Median (range) | 64 (37-76) |
 | < 45 | 2 (8) |
 | 45 - 64 | 10 (44) |
 | ≥ 65 | 11 (48) |
KPS | 90 | 10 (43) |
 | 80 | 13 (57) |
Histologic type | Papillary | 19 (83) |
 | Poorly differentiated | 4 (17) |
Recurrence | Primary tumor | 8 (35) |
 | Recurrent tumor | 15 (65) |
T stage at initial diagnosis | T1-2 | 1 (4) |
 | T3 | 14 (61) |
 | T4 | 8 (35) |
N stage at initial diagnosis | N0 | 4 (17) |
 | N1a | 10 (44) |
 | N1b | 9 (39) |
AJCC Stage at initial diagnosis | I-II | 3 (12) |
 | III | 10 (44) |
 | IVA | 10 (44) |
T stage at pre-EBRT | T0-2 | 3 (13) |
 | T3 | 3 (13) |
 | T4 | 17 (74) |
N stage at pre-EBRT | N0 | 3 (13) |
 | N1a | 4 (17) |
 | N1b | 16 (70) |
AJCC Stage at pre-EBRT | I-III | 3 (13) |
 | IVA | 14 (61) |
 | IVB | 1 (4) |
 | IVC | 5 (22) |
Tg* level(ng/mL) | Median (range) | 10 (0.2-1411) |
 | < 10 | 11 (48) |
 | ≥ 10 | 12 (52) |
Thyroid surgery | Subtotal thyroidectomy | 4 (17) |
 | Total thyroidectomy | 19 (83) |
Lymph node surgery | CND | 6 (26) |
 | CND+Unilateral SND/MRND | 14 (61) |
 | CND+Bilateral SND/MRND | 3 (13) |
Postoperative residuum | No | 3 (13) |
 | Microscopic | 2 (9) |
 | Macroscopic | 18 (78) |
Radioiodine treatment | No | 4 (17) |
 | Yes | 19 (83) |
EBRT volume | Limited field | 11 (48) |
 | Elective field | 12 (52) |
EBRT dose (EQD2, Gy) | Median (range) | 62.5 (60-69) |